Dyadic International (DYAI) Q4 2024 earnings summary

Executive summary

• Achieved strong revenue growth in 2024, with total revenue rising to $3.495 million from $2.899 million, driven by milestone and license payments, and a focus on near-term product commercialization and technology licensing.

• Advanced both non-pharmaceutical and biopharmaceutical pipelines, leveraging proprietary C1 and Dapibus platforms for alternative proteins, enzymes, and biologics, with six new products in development.

• Secured up to $7.5 million in grants from CEPI and Gates Foundation to accelerate C1 platform for vaccine and antibody manufacturing.

• Expanded global partnerships with leading organizations, including CEPI, Gates Foundation, Phibro, and industry collaborators, to accelerate platform adoption and product development.

• Positioned for first commercial product launches in 2025, with a robust pipeline and growing market demand for animal-free, high-performance proteins.

Financial highlights

• Revenue for 2024 increased to $3.495 million from $2.899 million in 2023, driven by $1 million in license revenue from Proliant and $890,000 from enzymes.

• Cash, cash equivalents, and investment-grade securities rose to $9.3 million as of year-end 2024, up from $7.3 million the prior year.

• R&D expenses decreased to $2.044 million from $3.297 million, reflecting completion of a Phase I clinical trial.

• G&A expenses increased to $6.135 million, mainly due to higher business development, investor relations, and share-based compensation.

• Net loss narrowed to $5.809 million ($0.20/share) from $6.795 million ($0.24/share) in 2023.

Outlook and guidance

• Anticipates first commercial product launches in recombinant albumin, non-animal dairy, DNase I, and cellulosic enzymes in 2025.

• Plans to begin sampling recombinant transferrin and FGF products in 2025, with further enzyme and protein launches expected by year-end.

• Expects additional revenue growth opportunities from recent and ongoing grant awards, including CEPI and Gates Foundation funding.

• Focused on expanding strategic partnerships and leveraging proprietary platforms to meet rising global demand for sustainable proteins.

• Ongoing optimization and sampling for human lactoferrin and dairy enzymes, with launches targeted for late 2025.